source
- Beam Therapeutics reports year-long reduction in sickle cell crises in phase 1/2 risto-cel studyBeam Therapeutics disclosed data from its phase 1/2 trial of risto-cel, a base-edited autologous cell therapy targeting the BCL11A gene in sickle cell disease. The trial enrolled 31 adults and ado…
- FDA approves Bayer's Sunharbo, a new class drug to lower stroke recurrenceThe FDA has given its nod to a Bayer medication designed to cut the risk of another stroke in patients who have already suffered one. The product, marketed as Sunharbo, belongs to a newly created…